NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 9 June 2022, 09:30am.

**Location:** Via Zoom Conference Call

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Laura Bojke Present for all items
4. Maria Brezitski Present for items 1 – 5.3.2
5. Professor Iolo Doull Present for all items
6. Dr James Fotheringham Present for all items
7. Professor Nicholas Latimer Present for all items
8. Professor David McAllister Present for all items
9. Dr Rhiannon Owen Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Mary Weatherstone Present for items
13. Professor Nicky Welton Present for items
14. Nigel Westwood Present for all items
15. Peter Wheatley-Price Present for all items
16. Tony Wootton Present for all items

NICE staff present

Richard Diaz, Associate Director Present for items 1 – 4.1.3 & 5 – 6.3.2

Henry Edwards, Associate Director Present for items 4.1.3 – 4.2.2

Daniel Davies, Project Manager Present for items 5 – 6.3.2

Jeremy Powell, Project Manager Present for items 1 – 4.2.2

Adam Brooke, HTA Adviser Present for items 5 – 6.3.2

Yelan Guo, HTA Adviser Present for items 1 – 4.2.2

George Braileanu, HTA Analyst Present for items 5 – 6.3.2

Emily Leckenby, HTA Analyst Present for items 1 – 4.2.2

Sam Slayen, HTA Analyst Present for items 5 – 6.3.2

Giacomo De Guisa, Technical Analyst, Present for items 5 – 5.3.2

Philip Williams, Business Analyst, RIA Present for all items

Rebecca Thomas, Assistant HTA Analyst Present for items 1 – 4.2.2

Helen Barnett, Senior Medical Editor Present for items 1 – 4.2.2

Ruth Melville, Senior Medical Editor Present for items 5 – 5.3.2

Anna Sparshatt, Senior Medical Editor Present for items

Rachel Calzay, Medical Editor Present for items 5 – 5.1.3

Catherine Pank, Assistant Project Manager, COT Present for items 1 – 4.2.2 &

Sandra Robinson, Assistant Project Manager, MiP Present for items 5 – 5.1.3

Ella Fitzpatrick, Public Involvement Adviser, PiP Present for items 1 – 4.1.4

Mandy Tonkinson, Public Involvement Adviser, PiP Present for items 5 – 5.1.3 & 6 – 6.1.3

Rosalee Mason, Coordinator, MIP Present for items 1 – 4.1.4 & 5- 5.1.3

Ian Cannell, Administrator, TA Present for items 5 – 5.3.2

Emma Gordon, Administrator, TA Present for items 6 – 6.3.2

Laura Kelly, Administrator, COT Present for all items

External assessment group representatives present

Mark Corbett, University of York External Assessment Group Present for items 1 – 4.1.4, 5 – 5.2.1 & 6 – 6.2.1

Edward Cox, University of York External Assessment Group Present for items 1 – 4.1.4

Ana Duarte, University of York External Assessment Group Present for items 5 – 5.2.1

Pedro Saramago, University of York External Assessment Group Present for items 1 – 4.1.4

Matthew Walton, University of York External Assessment Group Present for items 6 – 6.2.1

Clinical & Patient experts present

Dr Nichola Cooper, Consultant Haematologist nominated by Swedish Orphan Biovitrum. Present for items 1 – 4.1.4

Dr Quentin Hill, Consultant Haematologist, nominated by the UK ITP forum. Present for items 1 – 4.1.4

Mervyn Morgan, CEO, ITP Support Association, Patient Representative, nominated by ITP Association Present for items 1 – 4.1.4

Dianne White, Patient Representative, nominated by ITP Association. Present for items 1 – 4.1.4

Frances Reid, Programme Director, World Ovarian Cancer Coalition, nominated by the National Axial Spondyloarthritis Society (NASS). Present for items 5 – 5.1.3 & 6 – 6.1.3

Dr Raj Sengupta, Consultant Rheumatologist, nominated by AbbVie. Present for items 5 – 5.1.3 & 6 – 6.1.3

Lara Wiseman, Patient Representative, nominated by National Axial Spondyloarthritis Society (NASS) Present for items 5 – 5.1.3

Thomas Prior, Patient Representative, nominated by National Axial Spondyloarthritis Society (NASS) Present for items 6 – 6.1.3

Observers present

Rachel Russell, Appeals Panel Member, NICE Present for items 1 – 4.1.4

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Stephen Smith, Toby Smith, Stuart Williams & Laura Bojke.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 12 May.

### Appraisal of Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Swedish Orphan Biovitrum.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Mervyn Morgan declared an indirect financial interest, as the ITP Support Association have received a grant from Swedish Orphan Biovitrum. It was agreed that this declaration would not prevent Mervyn Morgan from providing expert advice in this discussion.
* Dr Nichola Cooper declared a direct financial interest as she has received honoraria (speaker fees and advisory boards) from Sobi, Amgen, ReAlta, Grifols, and Novartis, and has received research support from Novartis. It was agreed that this declaration would not prevent Dr Cooper from providing expert advice in this discussion.
* Dr Quentin Hill declared a direct financial as he has participated in consultancy or lecturing for: Alexion, Amgen, Apellis, Argenx, Grifols, Novartis, ReAlta, Sanofi, Janssen, Immunovant and Incyte and completed Sobi’s ITP clinicians for NICE survey, for which he was renumerated. It was agreed that this declaration would not prevent Dr Hill from providing expert advice in this discussion.
* Dr James Fotheringham declared a direct financial interest as he has participated in an Advisory Board meeting for Novartis, about risk prediction tools in kidney transplantation, and honorarium was paid to directly to himself. It was agreed this this declaration would not prevent Dr Fotheringham from participating in this discussion.
* Professor Nick Latimer declared a direct financial interest as in October 2021, he gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as the manufacturer of a comparator. It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion.
* Rachel Russell declared a direct financial interest as she is a Pfizer employee. Although Pfizer do not have assets in thrombocytopenia, Rachel does have shares in GSK (as past employee of a company they bought out (Wellcome). GSK has a thrombocytopenia asset called Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293). It was agreed that this declaration would not prevent Rachel Russell from observing this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Professor Iolo Doull (Clinical) Peter Wheatley Price (Cost) & Nigel Westwood (Lay)
    2. The committee discussed confidential information submitted for this item.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10738>

### Appraisal of Tofacitinib for treating active ankylosing spondylitis [ID3865]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Peter Wheatley-Price declared various direct professional and personal interest as he has lived with Ankylosing Spondylitis since aged 23 and have previously been treated with etanercept and adalumimab, and is currently on golumimab. Peter Wheatley-Price had also previously served for 12 years as a trustee for the patient organisation (National Ankylosing Spondylitis Society now National Axial Spondyloarthritis Society.) He is currently a member but not active in any way. It was agreed that this declaration would not prevent Peter Wheatley-Price from participating in this discussion.
* Dr James Fotheringham declared a direct financial interest as he has participated in an Advisory Board meeting for Novartis, about risk prediction tools in kidney transplantation, and honorarium was paid to directly to himself. It was agreed this this declaration would not prevent Dr Fotheringham from participating in this discussion.
* Professor Nick Latimer declared a direct financial interest as in October 2021, he gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as the manufacturer of a comparator
* Frances Reid declared a direct non-financial interest prior to the meeting, as she is Programme Director for the World Ovarian Cancer Coalition and is involved in global advocacy efforts particularly improvements to diagnosis, awareness of symptoms and access to treatments (in low- and middle-income countries). Frances Reid also declared a direct financial interest as she was renumerated for speaking about her experience living with Ankylosing Spondylitis at engagement arranged for Novartis Employees. It was agreed that these declarations would not prevent Frances Reid from providing expert advice in this discussion.
* Dr Raj Sengupta declared direct financial interests as he has received honoraria, grants and conference support from Abbvie, Biogen, Celgene, Lilly, Novartis, Roche and UCB. It was agreed that this declaration would not prevent Dr Sengupta from providing expert advice in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee.. This information was presented to the committee by the lead team – Dr James Fotheringham (Clinical) Dr Rhiannon Owen (Cost) & Tony Wootton (Lay)
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10771>

### Appraisal of Upadacitinib for treating active ankylosing spondylitis [ID3848]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AbbVie.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* The interests declared in the previous technology also apply to this appraisal. As the vast majority of those in attendance for this topic were also present for the discussion of ID3865– the chair agreed that these did not need to be verbally declared again during this meeting.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team – Dr James Fotheringham (Clinical), Dr Rhiannon Owen (Cost) & Tony Wootton (Lay)
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10735>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 13 July 2022 and will start promptly at 10am.